Epilepsy in Developmental and Rare Neurological Disorders
Jazz Pharmaceuticals Research UK Limited is involved in clinical research for severe childhood-onset seizure disorders, with a focus on Dravet syndrome and Lennox-Gastaut syndrome. Its studies address uncontrolled seizures and the broader neurological burden associated with these conditions.
- Dravet syndrome
- Lennox-Gastaut syndrome
- Seizure control
The sponsor’s trial activity in this area reflects interest in treatment options for refractory epilepsy across paediatric and adolescent populations.
Tuberous Sclerosis Complex and Associated Neurological Manifestations
Another major area of interest is tuberous sclerosis complex, including seizure-related symptoms and co-occurring behavioural outcomes. The research includes attention to the impact of epilepsy on daily functioning in affected participants.
- Tuberous sclerosis complex
- Behavioural outcomes
- Co-occurring neurological symptoms
These studies extend across a wide age range, indicating sustained clinical interest in the neurological and functional consequences of this rare disorder.
Cannabidiol-Based Therapeutic Research
The sponsor funds research involving cannabidiol oral solution as adjunctive therapy in rare epilepsy syndromes. This includes evaluation of treatment effects in participants with inadequately controlled seizures linked to developmental epileptic encephalopathies.
- Cannabidiol oral solution
- Adjunctive therapy
- Rare epilepsy syndromes
Its clinical programme also explores the relationship between treatment use and seizure frequency in these disorders.
Paediatric Neurology and Early-Life Seizure Disorders
Jazz Pharmaceuticals Research UK Limited is active in paediatric neurology, with studies spanning infants, children, and young adults affected by severe seizure disorders. The research landscape includes very early-onset disease and age-specific clinical needs.
- Paediatric epilepsy
- Infant and early-childhood seizure disorders
- Age-specific neurological care
This focus supports investigation of therapies for patients at different developmental stages where seizure burden and associated symptoms are clinically significant.
